AI Drug Discovery Stocks
Biotechs built on machine-learning platforms for finding and designing drugs.
As of Oct 30, 2026, AI Drug Discovery has 11 US-listed companies worth $16.9B combined. The median member moved +4.0% over the past week; ABSI led at +21.2% and EVAX trailed at -22.1%.
Companies in AI Drug Discovery
- RLAY – Relay Therapeutics Inc, $4.1B
- ABCL – Abcellera Biologics Inc, $3.8B
- RXRX – Recursion Pharmaceuticals Inc, $1.9B
- GENB – Generate Biomedicines, Inc. Common Stock, $1.8B
- SDGR – Schrodinger Inc, $1.8B
- ABSI – Absci Corp, $1.6B
- CERT – Certara Inc, $1.6B
- HYFT – ImmunoPrecise Antibodies Ltd., $60.8M
- EVAX – Evaxion Biotech AS, $36.5M
- LTRN – Lantern Pharma Inc, $9.3M
- BFRG – Bullfrog AI Holdings, Inc. Common Stock, $9.2M